This Article Full Text Full Text (PDF) All Versions of this Article: 47/1/19    most recent 01.HYP.0000196276.29211.6fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pollock, J. S. Articles by Carmines, P. K. Search for Related Content PubMed PubMed Citation Articles by Pollock, J. S. Articles by Carmines, P. K. Related Collections Other hypertension

(Hypertension. 2006;47:19.)
© 2006 American Heart Association, Inc.

Editorial Commentaries

NOS3 Regulation

Renal Tubular Epithelial Cells Are Not Simply Large Endothelial Cells

From the Vascular Biology Center (J.S.P.), Department of Pharmacology, Medical College of Georgia, Augusta, and the Department of Cellular & Integrative Physiology (P.K.C.), University of Nebraska College of Medicine, Omaha.

Correspondence to Jennifer S. Pollock, PhD, Professor, Vascular Biology Center, CB 3213, 1459 Laney-Walker Blvd, Medical College of Georgia, Augusta, GA 30912. E-mail jpollock@mcg.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Endothelial nitric oxide synthase (NOS3) was first purified and characterized in 1991 as the enzyme responsible for the production of the endothelium-dependent relaxation factor. NOS3 converts L-arginine and molecular oxygen to L-citrulline and NO. Over the last 14 years, regulation of NOS3 enzymatic activity has been shown to be mediated by transcription and translation, substrate and cofactor availability, subcellular localization, protein–protein interactions, and phosphorylation.

NOS3 is a homodimer with each monomer possessing a reductase domain (FMN, FAD, and NADPH binding region) and an oxygenase domain (arginine, heme, Fe, and tetrahydrobiopterin binding region) that are "linked" by the calmodulin-binding domain (CBD). NOS3 activity is Ca²⁺/calmodulin-dependent, and it has been proposed that calmodulin binds to the CBD and relieves the inhibition from the auto-inhibitory loop, thereby enabling the flow of electrons from the reductase domain to the oxygenase domain and the production of NO. "Uncoupled NOS" refers to the condition in which O₂ is the final electron acceptor and thus NOS produces O₂^·–. NOS3 is also known to be myristoylated and palmitoylated at the amino-terminal region, which renders the enzyme membrane-bound and has been described to be active in the plasma membrane and golgi. However, there is evidence that under pathological conditions, NOS3 is upregulated and expressed in the cytosolic compartment.¹ NOS3 is known to interact with numerous proteins that modulate enzymatic activity under normal and pathological conditions.

The overwhelming majority of studies regarding regulation, and especially phosphorylation, of NOS3 have been described in the vasculature and particularly . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Herrera, N. J. Hong, P. A. Ortiz, and J. L. Garvin Endothelin-1 Inhibits Thick Ascending Limb Transport via Akt-stimulated Nitric Oxide Production J. Biol. Chem., January 16, 2009; 284(3): 1454 - 1460. [Abstract] [Full Text] [PDF]

				M. S. Forbes, B. A. Thornhill, M. H. Park, and R. L. Chevalier Lack of Endothelial Nitric-Oxide Synthase Leads to Progressive Focal Renal Injury Am. J. Pathol., January 1, 2007; 170(1): 87 - 99. [Abstract] [Full Text] [PDF]